Pfizer said in a release that it has enhanced its stable of oncology therapies with the March 31 announcement that the FDA has expanded the drugmaker's Ibrance medication for treatment of metastatic breast cancer in post-menopausal women.
Merck and Pfizer Inc. said the U.S. Food and Drug Administration (FDA) has agreed to review three New Drug Applications for medications containing ertugliflozin that treat glycemic control in adults with type 2 diabetes.
Stakeholders and the public can hear a live webcast of Pfizer’s conference call planned for 10 a.m. EST on Jan. 31 featuring investment analysts and, additionally, access Pfizer’s 2016 fourth-quarter performance report online.
The Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC) recently released new recommendations for the dosing schedule of Trumenba (Meningococcal Group B) vaccinations.
Pfizer Inc. recently announced that it has granted over $1 million to finance the top breast cancer advocacy organizations that are dedicated to scientific research and quality-of-life studies concerning metastatic breast cancer (MBC).
Leaders with the European Medicines Agency recently announced that the organization has accepted the marketing authorization application for Xeljanz, a new treatment for moderate to severe rheumatoid arthritis, developed by Pfizer Inc.